Showing results (171-180 of 183) with videos related to

Sort By:
Pageof 19
Alimentary Pharmacology & Therapeutics|February 28, 2017
Intra-patient variability in adalimumab drug levels within and between cycles in Crohn's diseaseM G Ward, P A Thwaites, L Beswick, et al.
Internal Medicine Journal|April 15, 2015
Seasonal recurrence of food bolus obstruction in eosinophilic esophagitisH L Philpott, S Nandurkar, F Thien, et al.
Journal of Human Nutrition and Dietetics : the Official Journal of the British Dietetic Association|August 6, 2013
Dietary sorbitol and mannitol: food content and distinct absorption patterns between healthy individuals and patients with irritable bowel syndromeC K Yao, H-L Tan, D R van Langenberg, et al.
Internal Medicine Journal|December 22, 2009
Use and abuse of faecal occult blood tests in an acute hospital inpatient settingA Friedman, A Chan, L C Chin, et al.
Alimentary Pharmacology & Therapeutics|January 28, 2010
Dietary poorly absorbed, short-chain carbohydrates increase delivery of water and fermentable substrates to the proximal colonJ S Barrett, R B Gearry, J G Muir, et al.
The Medical Journal of Australia|June 5, 1995
Appropriateness of transfusions of red cells, platelets and fresh frozen plasma. An audit in a tertiary care teaching hospitalJ Metz, K M McGrath, M L Copperchini, et al.
Alimentary Pharmacology & Therapeutics|February 23, 2018
Randomised clinical trial: efficacy, safety and dosage of adjunctive allopurinol in azathioprine/mercaptopurine nonresponders (AAA Study)A B Friedman, S J Brown, P Bampton, et al.
Alimentary Pharmacology & Therapeutics|May 9, 2017
Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factorsM G Ward, B Warner, N Unsworth, et al.
Scientific Reports|October 21, 2020
Nutritional profile of rodent diets impacts experimental reproducibility in microbiome preclinical researchC J Tuck, G De Palma, K Takami, et al.
Alimentary Pharmacology & Therapeutics|January 30, 2018
Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel diseaseB Christensen, D Micic, P R Gibson, et al.
Pageof 19